LQDA
Bearish signalScored 2026-10-24 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Liquidia Corporation
- Nom
- Liquidia Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Pharmaceuticals
- Bourse
- NASDAQ
- Capitalisation
- $3.8B
- Employés
- 216
- PDG
- Roger A. Jeffs
- Site web
- https://www.liquidia.com
- Marché
- AVLNINSMUTHRVCRE
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 50 236 titres (~2 112 001,73 $ US)
- Insiders
- JEFFS ROGERSINGH RAMAN
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$17,081,135
Avg sell (VWAP, 90d window) $57.45 vs last close $43.74 (-23.9%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$9,929,476 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-12
- Liquidity
- Liquid $329,693,826/day · 20d vol
- Last synced
-
2026-10-26 21:10:39
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-12 | Adair Jason | Sell · S · 10b5-1 | 7,301 | $28.48 | $207,932 | Form 4 |
| 2026-10-12 | Boyle Dana | Sell · S · 10b5-1 | 5,892 | $28.48 | $167,804 | Form 4 |
| 2026-10-12 | JEFFS ROGER | Sell · S · 10b5-1 | 32,744 | $28.48 | $932,549 | Form 4 |
| 2026-10-12 | Kaseta Michael | Sell · S · 10b5-1 | 18,938 | $28.48 | $539,354 | Form 4 |
| 2026-10-12 | Khindri Sanjeev | Sell · S · 10b5-1 | 1,101 | $28.48 | $31,356 | Form 4 |
| 2026-10-12 | Krepp Sarah | Sell · S · 10b5-1 | 5,245 | $28.48 | $149,378 | Form 4 |
| 2026-10-12 | Moomaw Scott | Sell · S · 10b5-1 | 8,863 | $28.48 | $252,418 | Form 4 |
| 2026-10-12 | Saggar Rajeev | Sell · S · 10b5-1 | 9,218 | $28.48 | $262,529 | Form 4 |
| 2026-10-12 | Schundler Russell | Sell · S · 10b5-1 | 13,692 | $28.48 | $389,948 | Form 4 |
| 2026-09-14 | SINGH RAMAN | Sell · S | 8,468 | $66.16 | $560,243 | Form 4 |
| 2026-09-11 | SINGH RAMAN | Sell · S | 9,024 | $68.62 | $619,210 | Form 4 |
| 2026-09-01 | Krepp Sarah | Sell · S · 10b5-1 | 274 | $67.76 | $18,566 | Form 4 |
| 2026-08-21 | Adair Jason | Sell · S · 10b5-1 | 41,832 | $69.09 | $2,890,206 | Form 4 |
| 2026-08-20 | Rielly-Gauvin Katherine | Sell · S · 10b5-1 | 18,393 | $72.23 | $1,328,477 | Form 4 |
| 2026-08-19 | Rielly-Gauvin Katherine | Sell · S · 10b5-1 | 36,789 | $74.99 | $2,758,958 | Form 4 |
| 2026-08-19 | Saggar Rajeev | Sell · S | 50,000 | $74.06 | $3,702,825 | Form 4 |
| 2026-08-17 | Saggar Rajeev | Sell · S | 29,534 | $76.84 | $2,269,381 | Form 4 |
| 2026-07-27 | Adair Jason | Sell · S · 10b5-1 | 688 | $87.53 | $60,221 | Form 4 |
| 2026-07-27 | Boyle Dana | Sell · S · 10b5-1 | 1,600 | $87.53 | $140,048 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-24 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
LQDA presents a deeply concerning risk profile: a liquidity score of 25 and a fundamentals trend score of 35 reflect severe financial distress, with the current ratio collapsing from 4.43 to 1.40 in a single year and…
The first sentence of the analysis written for LQDA on 2026-10-24 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Pulls against a bullish reading. Current ratio 1.40 · operating margin -32%
Suggested stop 35.01, nearest stored support minus 0.5 ATR(20.0% under the last close). Reward/risk to the next stored resistance is 1.76. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-21 Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) investors concerning the Company''s and/or members of its senior management''s possible violation of the federal securities laws and other unlawful business practices. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened?
- 2026-10-14 LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
- 2026-10-14 Liquidia shares surge 25% as settlement ends United Therapeutics litigation Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia''s inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
- 2026-10-14 United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42% A patent court ruling wiped out nearly half of Liquidia''s stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
- 2026-10-14 Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday U.S. stocks were mostly lower, with the Nasdaq Composite falling around 200 points on Wednesday.
- 2026-10-14 This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario. Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
- 2026-10-13 Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption.
- 2026-10-12 Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky Liquidia Corporation (LQDA) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Oct. 12, 2026Liquidia shareholders took a roughly 57% loss af
- 2026-10-12 Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigation risk before the losses occurred.
- 2026-10-12 Liquidia (NASDAQ:LQDA) Shares Gap Up – Here’s Why Liquidia Corporation (NASDAQ: LQDA - Get Free Report)''s stock price gapped up prior to trading on Monday. The stock had previously closed at $27.38, but opened at $29.27. Liquidia shares last traded at $29.0220, with a volume of 955,427 shares. Analyst Upgrades and Downgrades A number of equities research analysts have commented on the company. Wedbush
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 91.6% | 58.0% | 83.5% | 82.1% | 76.5% | |
| Ebit Margin | -28.3% | -842.4% | -413.0% | -242.7% | -263.1% | |
| Ebitda Margin | -27.3% | -826.7% | -400.6% | -219.8% | -219.4% | |
| Operating Profit Margin | -32.5% | -866.6% | -419.6% | -243.3% | -263.0% | |
| Pretax Profit Margin | -43.5% | -931.7% | -448.9% | -257.4% | -269.0% | |
| Continuous Operations Profit Margin | -43.5% | -931.7% | -448.9% | -257.4% | -269.0% | |
| Net Profit Margin | -43.5% | -931.7% | -448.9% | -257.4% | -269.0% | |
| Bottom Line Profit Margin | -43.5% | -931.7% | -448.9% | -257.4% | -269.0% | |
| Current Ratio | 1.404 | 4.430 | 4.846 | 11.342 | 8.363 | |
| Quick Ratio | 1.404 | 4.425 | 4.846 | 11.342 | 8.363 | |
| Solvency Ratio | -0.238 | -0.838 | -1.074 | -0.964 | -1.018 | |
| Cash Ratio | 1.404 | 4.224 | 4.511 | 10.600 | 7.847 | |
| Price To Earnings Ratio | -43.112 | -7.084 | -9.942 | -9.507 | -6.957 | |
| Price To Earnings Growth Ratio | 0.832 | -0.190 | -0.123 | 2.218 | 0.116 | |
| Forward Price To Earnings Growth Ratio | 0.832 | -0.190 | -0.123 | 2.218 | 0.116 | |
| Price To Earnings Diluted Ratio | -43.112 | -7.084 | -9.942 | -9.507 | -6.957 | |
| Price To Earnings Diluted Growth Ratio | 0.832 | -0.190 | -0.123 | 2.218 | 0.116 | |
| Price To Book Ratio | 66.331 | 11.978 | 16.532 | 4.294 | 3.707 | |
| Price To Sales Ratio | 18.748 | 66.133 | 44.709 | 24.368 | 18.823 | |
| Price To Free Cash Flow Ratio | -74.164 | -9.409 | -18.245 | -13.307 | -7.086 | |
| Price To Operating Cash Flow Ratio | -83.175 | -9.908 | -18.811 | -13.583 | -7.108 | |
| Debt To Assets Ratio | 0.604 | 0.531 | 0.419 | 0.189 | 0.172 | |
| Debt To Equity Ratio | 4.423 | 1.584 | 1.047 | 0.271 | 0.246 | |
| Debt To Capital Ratio | 0.816 | 0.613 | 0.512 | 0.213 | 0.198 | |
| Long Term Debt To Capital Ratio | 0.748 | 0.558 | 0.479 | 0.180 | 0.138 | |
| Financial Leverage Ratio | 7.328 | 2.980 | 2.502 | 1.429 | 1.436 | |
| Working Capital Turnover Ratio | 1.597 | 0.130 | 0.215 | 0.220 | 0.237 | |
| Operating Cash Flow Ratio | -0.263 | -2.236 | -2.241 | -3.249 | -4.645 | |
| Operating Cash Flow Sales Ratio | -0.225 | -6.675 | -2.377 | -1.794 | -2.648 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.122 | 1.053 | 1.031 | 1.021 | 1.003 | |
| Debt Service Coverage Ratio | -0.523 | -3.794 | -7.882 | -14.983 | -37.014 | |
| Interest Coverage Ratio | -2.125 | -9.714 | -11.698 | -16.583 | -44.353 | |
| Short Term Operating Cash Flow Coverage Ratio | -0.611 | -5.186 | -15.894 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.180 | -0.763 | -0.839 | -1.169 | -2.117 | |
| Capital Expenditure Coverage Ratio | -8.230 | -18.877 | -32.220 | -48.291 | -318.084 | |
| Dividend Paid And Capex Coverage Ratio | -8.230 | -18.877 | -32.220 | -48.291 | -318.084 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -68.837 | -7.532 | -10.674 | -9.120 | -7.109 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 91.6% | ▲33.6% | ▲13.3% |
| Ebit Margin | -28.3% | ▲814.2% | ▲329.6% |
| Ebitda Margin | -27.3% | ▲799.4% | ▲311.5% |
| Operating Profit Margin | -32.5% | ▲834.2% | ▲332.5% |
| Pretax Profit Margin | -43.5% | ▲888.1% | ▲346.6% |
| Continuous Operations Profit Margin | -43.5% | ▲888.1% | ▲346.6% |
| Net Profit Margin | -43.5% | ▲888.1% | ▲346.6% |
| Bottom Line Profit Margin | -43.5% | ▲888.1% | ▲346.6% |
| Current Ratio | 1.405 | ▼-3.026 | ▼-4.673 |
| Quick Ratio | 1.405 | ▼-3.020 | ▼-4.672 |
| Solvency Ratio | -0.238 | ▲0.600 | ▲0.588 |
| Cash Ratio | 1.405 | ▼-2.820 | ▼-4.313 |
| Price To Earnings Ratio | -43.112 | ▼-36.028 | ▼-27.792 |
| Price To Earnings Growth Ratio | 0.832 | ▲1.023 | ▲0.262 |
| Forward Price To Earnings Growth Ratio | 0.832 | ▲1.023 | ▲0.262 |
| Price To Earnings Diluted Ratio | -43.112 | ▼-36.028 | ▼-27.792 |
| Price To Earnings Diluted Growth Ratio | 0.832 | ▲1.023 | ▲0.262 |
| Price To Book Ratio | 66.331 | ▲54.353 | ▲45.762 |
| Price To Sales Ratio | 18.748 | ▼-47.385 | ▼-15.808 |
| Price To Free Cash Flow Ratio | -74.164 | ▼-64.754 | ▼-49.721 |
| Price To Operating Cash Flow Ratio | -83.175 | ▼-73.267 | ▼-56.658 |
| Debt To Assets Ratio | 0.604 | ▲0.072 | ▲0.221 |
| Debt To Equity Ratio | 4.423 | ▲2.839 | ▲2.909 |
| Debt To Capital Ratio | 0.816 | ▲0.203 | ▲0.345 |
| Long Term Debt To Capital Ratio | 0.748 | ▲0.191 | ▲0.328 |
| Financial Leverage Ratio | 7.329 | ▲4.348 | ▲4.193 |
| Working Capital Turnover Ratio | 1.597 | ▲1.467 | ▲1.117 |
| Operating Cash Flow Ratio | -0.263 | ▲1.973 | ▲2.264 |
| Operating Cash Flow Sales Ratio | -0.225 | ▲6.449 | ▲2.518 |
| Free Cash Flow Operating Cash Flow Ratio | 1.121 | ▲0.069 | ▲0.076 |
| Debt Service Coverage Ratio | -0.523 | ▲3.270 | ▲12.316 |
| Interest Coverage Ratio | -2.125 | ▲7.589 | ▲14.769 |
| Short Term Operating Cash Flow Coverage Ratio | -0.611 | ▲4.574 | ▲3.727 |
| Operating Cash Flow Coverage Ratio | -0.180 | ▲0.583 | ▲0.833 |
| Capital Expenditure Coverage Ratio | -8.230 | ▲10.647 | ▲76.910 |
| Dividend Paid And Capex Coverage Ratio | -8.230 | ▲10.647 | ▲76.910 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -68.837 | ▼-61.306 | ▼-48.183 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.97B | $925.6M | $781.9M | $388.3M | $241.9M | |
| Enterprise value | $2.98B | $871.5M | $747.7M | $319.5M | $200.5M | |
| EV / Sales | 18.79x | 62.27x | 42.76x | 20.05x | 15.60x | |
| EV / Op. cash flow | -83.38x | -9.33x | -17.99x | -11.18x | -5.89x | |
| EV / Free cash flow | -74.34x | -8.86x | -17.45x | -10.95x | -5.87x | |
| EV / EBITDA | -68.84x | -7.53x | -10.67x | -9.12x | -7.11x | |
| Net debt / EBITDA | -0.17x | 0.47x | 0.49x | 1.97x | 1.47x | |
| Current ratio | 1.40x | 4.43x | 4.85x | 11.34x | 8.36x | |
| Income quality | 0.52x | 0.72x | 0.53x | 0.70x | 0.98x | |
| Graham net-net | -$1 | $0 | $0 | $1 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 154.0% | 110.6% | 108.7% | 106.0% | 102.3% | |
| Working capital | $54.9M | $143.3M | $71.3M | $91.0M | $53.9M | |
| Invested capital | $61.8M | $162.9M | $84.9M | $104.9M | $69.7M | |
| Return on assets | -21.0% | -56.6% | -66.3% | -31.7% | -36.9% | |
| Operating ROA | -18.4% | -69.6% | -59.3% | -34.8% | -35.0% | |
| Return on tangible assets | -21.5% | -58.4% | -70.7% | -33.7% | -40.5% | |
| Return on equity | -154.0% | -168.7% | -166.0% | -45.4% | -53.0% | |
| Return on invested capital | -20.5% | -58.6% | -70.9% | -31.9% | -38.6% | |
| Return on capital employed | -26.7% | -64.3% | -73.5% | -32.2% | -39.1% | |
| Earnings yield | -2.3% | -14.1% | -10.0% | -10.6% | -14.3% | |
| Free cash flow yield | -1.3% | -10.6% | -5.5% | -7.5% | -14.1% | |
| Capex / Op. cash flow | -12.2% | -5.3% | -3.1% | -2.1% | -0.3% | |
| Capex / Depreciation | 283.8% | 225.3% | 59.2% | 16.2% | 1.9% | |
| Capex / Sales | 2.7% | 35.4% | 7.4% | 3.7% | 0.8% | |
| SG&A / Sales | 99.3% | 582.8% | 255.8% | 203.4% | 179.8% | |
| R&D / Sales | 24.8% | 341.8% | 247.3% | 122.0% | 159.6% | |
| Stock comp / Sales | 18.6% | 134.4% | 57.7% | 58.3% | 52.5% | |
| Intangibles / Total assets | 2.1% | 3.1% | 6.2% | 5.9% | 8.8% | |
| Days sales outstanding | 125d | 71d | 85d | 115d | 85d | |
| Days payables outstanding | 101d | 291d | 176d | 280d | 129d | |
| Operating cycle | 125d | 86d | 85d | 115d | 85d | |
| Cash conversion cycle | 23d | -205d | -92d | -166d | -44d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years